Sionna Stock 144% This Year: Is the Biotech a Buy Now?
Sionna Therapeutics has surged 144% over the past year, drawing attention from growth-minded investors. This article ...
Review which Dividend Aristocrats ETF has the highest management fee and how it affects net performance.
28,021 articlesSionna Therapeutics has surged 144% over the past year, drawing attention from growth-minded investors. This article ...
Amundi, Europe's biggest asset manager, launches a UCITS-compliant Solana fund in partnership with SPiko Finance, mar...
A major hedge fund slashed its stake in Structure Therapeutics, prompting questions about the future path for GPCR-fo...
A single trading session can test even solid businesses. This article explains why autozone stock plummeting today ha...
Nebius stock has drawn attention for rapid AI cloud growth, but two core risks could derail momentum. This guide give...
A landmark $1.5 billion bet on counter-drone tech sets Motorola Solutions up for deeper public-safety leadership. Her...
Two giants in the U.S. cannabis space face off for investors: Green Thumb Industries and Curaleaf. This guide breaks ...
In 2026, the budget airline reinventing itself is pulling ahead as it monetizes upgrades and smarter distribution, wh...
BTCC reports rapid growth and a broader product slate in 2026, while safety, risk controls, and regulatory compliance...
The Pentagon has formally designated Anthropic as a supply chain risk, a move that could curtail access to defense co...
Turning Point Brands stock took a sharp drop this week as investors weighed a disappointing quarter and cautious guid...
Gold and silver slid this week as geopolitical risk and higher oil costs pressured bullion, while Bitcoin bucked the ...